Loading…
Manufactures synthetic DNA on a silicon-chip platform, selling genes and DNA libraries to biotech, pharma and diagnostics researchers.
Manufactures synthetic DNA on a silicon-chip platform, selling genes and DNA libraries to biotech, pharma and diagnostics researchers.
Sells synthetic DNA ordered online in many small orders, with revenue split across gene products, tools for preparing samples for sequencing, and antibody discovery services for drug developers. Orders come from a wide base of labs, so no single customer dominates, and most revenue is repeat consumables.
Moat: narrow (IP / patents, process know-how, scale). Proprietary silicon-based DNA synthesis technology enables lower-cost, higher-throughput gene manufacturing.
Headquarters: South San Francisco, California, US · Founded: 2013 · Employees: 979
Size Twist Bioscience (TWST) is a United States Health Care company (Biotechnology) with a market value of $7.95B, the 889th largest of 3,117 United States companies the cockpit tracks. Shares closed at $120.79 on 6 Nov 2026.
Performance Over six months the shares gained 112.5%, against +13.3% for the median peer and -1.1% for the United States market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue grew 19.2% over the last twelve months (peer median +26.0%); the operating margin is -31.9% (peer median 12.3%).
Valuation It trades at 18.2× enterprise value to sales against a peer median of 9.9× (5th most expensive of 16).
Capital Return on invested capital runs 45.2 points below its cost of capital (16.0% WACC).
Backlog Backlog (remaining performance obligations) was $21.9M at 30 Jun 2026, up 63% on a year earlier — 0.1 years of trailing revenue. Backlog detail →
Short interest Short interest is 15.5% of the free float (15 Oct 2026).
Next results Next results expected around 12 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $432M | $377M | $313M | $245M | $204M |
| Revenue growth | — | +20% | +28% | +20% | — |
| Gross profit | $224M | $191M | $133M | $89.7M | $84.2M |
| EBITDA | -$112M | -$111M | -$144M | -$178M | -$212M |
| Net income | -$137M | -$77.7M | -$209M | -$205M | -$218M |
| Free cash flow | -$93.1M | -$75.6M | -$69.2M | -$170M | -$226M |
| Capital expenditure | $40.2M | $28.0M | $5.08M | $27.8M | $102M |
| Total debt | $93.6M | $75.6M | $85.0M | $94.1M | $94.9M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Twist Bioscience TWST | $7.95B | +112% | +19% | -32% | 18.2× | n/a |
| Danaher DHR | $162B | +35% | +6% | 21% | 7.2× | 20.5% |
| Thermo Fisher Scientific TMO | $257B | +50% | +8% | 19% | 6.2× | 20.9% |
| Azenta AZTA | $1.72B | +104% | +1% | -3% | 2.4× | 56.0% |
| Agilent Technologies A | $49.3B | +51% | +9% | 24% | 7.0× | 22.6% |
| Eurofins Scientific ERF.PA | $17.5B | +49% | +3% | 12% | 2.8× | 13.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | TWST | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -20.6% | -0.6% | 5th lowest of 21 |
| 6-month return | +112.5% | +13.3% | 3rd highest of 21 |
| Distance from 52-week high | -45.0% | -25.8% | 3rd lowest of 21 |
| Revenue growth (TTM) | +19.2% | +26.0% | 6th lowest of 16 |
| Operating margin | -31.9% | 12.3% | 4th lowest of 16 |
| EV / Sales | 18.2× | 9.9× | 5th most expensive of 16 |
| ROIC minus cost of capital | -45.2 pp | -0.7 pp | 4th lowest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Twist Bioscience TWST | United States | $7.95B | +112% | +19% | -32% | 18.2× | n/a | n/a |
| 10x Genomics TXG | United States | $7.72B | +174% | -4% | -14% | 11.8× | 41.8% | +16.6% |
| Arrowhead Pharmaceuticals ARWR | United States | $8.22B | -20% | +17% | -34% | 11.9× | n/a | n/a |
| Genscript Biotech 1548.HK | Hong Kong | $8.81B | +96% | +53% | 12% | 9.9× | 36.5% | +19.8% |
| Caris Life Sciences CAI | United States | $7.13B | +56% | +85% | 15% | 6.9× | 18.7% | +85.4% |
| Krystal Biotech KRYS | United States | $8.92B | -2% | +26% | 48% | 17.1× | 11.9% | +26.0% |
| Axsome Therapeutics AXSM | United States | $6.96B | -39% | +54% | -19% | 7.9× | n/a | n/a |
| CG Oncology CGON | United States | $6.74B | +9% | +1,030% | -4,056% | 917.8× | n/a | n/a |
| Immunovant IMVT | United States | $6.31B | +5% | n/a | n/a | n/a | n/a | n/a |
| Vaxcyte PCVX | United States | $10.1B | +21% | n/a | n/a | n/a | n/a | n/a |
| Kodiak Sciences KOD | United States | $6.24B | +142% | n/a | n/a | n/a | n/a | n/a |
| ALTEOGEN 196170.KS | South Korea | $10.3B | -46% | +61% | 53% | 43.0× | 29.8% | +38.5% |
| Sichuan Kelun Pharmaceutical 002422.SZ | China | $10.8B | +30% | 0% | 9% | 3.9× | 7.2% | +2.3% |
| BioMarin Pharmaceutical BMRN | United States | $10.9B | +4% | +20% | 19% | 3.9× | 6.5% | +12.0% |
| Scholar Rock SRRK | United States | $5.72B | -3% | n/a | n/a | n/a | n/a | n/a |
| Hangzhou Tigermed Consulting 3347.HK | Hong Kong | $5.65B | -1% | +22% | 10% | 5.6× | 28.3% | +15.6% |
| Kymera Therapeutics KYMR | United States | $11.2B | +53% | +134% | -396% | 101.2× | n/a | n/a |
| Bio-Techne TECH | United States | $11.4B | +51% | 0% | 22% | 9.4× | 31.3% | +5.5% |
| Cogent Biosciences COGT | United States | $5.49B | -9% | n/a | n/a | n/a | n/a | n/a |
| Anthem Biosciences ANTHEM.NS | India | $5.46B | +17% | -1% | 35% | 24.9× | 36.7% | +26.2% |
| Halozyme Therapeutics HALO | United States | $11.8B | +62% | +41% | 57% | 8.2× | 2.5% | +39.2% |
Twist Bioscience reported $21.9M of remaining performance obligations at 30 Jun 2026, up 63% from a year earlier and up 32% from the previous quarter. That is 0.1 years of trailing revenue already under contract. Book-to-bill last quarter: 1.04.